-
Journal of Clinical Oncology 01/2009; 27(4):646-7; author reply 647. · 18.37 Impact Factor
-
Journal of Clinical Oncology 03/2006; 24(4):720-1. · 18.37 Impact Factor
-
Mitchell S Cairo,
Richard Sposto,
Sherrie L Perkins,
Anna T Meadows,
Margo L Hoover-Regan, James R Anderson,
Stuart E Siegel,
Mark A Lones,
Nicole Tedeschi-Blok,
Marshall E Kadin,
Carl R Kjeldsberg,
John F Wilson,
Warren Sanger,
Erin Morris,
Mark D Krailo,
Jonathan L Finlay
[show abstract]
[hide abstract]
ABSTRACT: Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58% had lactate dehydrogenase (LDH) > or = 500 IU/l, 23% had M2 or M3 bone marrow (BM), and 12% demonstrated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients > or = 15-years-old compared with < 15-year-old was 34 +/- 7 versus 59 +/- 2% (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 +/- 5 versus 63 +/- 3% (P < 0.001), and the 4-year EFS with LDH > or = 500 IU/l compared with LDH < 500 IU/l was 49 +/- 3 versus 71 +/- 4% (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 +/- 6 versus 54 +/- 2%, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.
British Journal of Haematology 02/2003; 120(4):660-70. · 4.94 Impact Factor
-
Mitchell S Cairo,
Richard Sposto,
Margo Hoover-Regan,
Anna T Meadows, James R Anderson,
Stuart E Siegel,
Marshall E Kadin,
Carl R Kjeldsberg,
John F Wilson,
Sherrie L Perkins,
Mark A Lones,
Erin Morris,
Jonathan L Finlay
[show abstract]
[hide abstract]
ABSTRACT: We reviewed the clinical characteristics, treatment, and outcome of 67 children with localized and 212 with disseminated large-cell lymphoma (LCL) treated during a 20-year period in 5 consecutive Children's Cancer Group (CCG) non-Hodgkin's lymphoma (NHL) trials. Clinical outcomes for patients treated on the four earlier studies with moderate-dose chemotherapy administered over 12-18 months were compared with patients treated most recently with short, intensive therapy. Median age at diagnosis was 12 years (range: 0-19 years). Male to female ratio was 1.8:1.0. Five-year event-free survival (EFS) was 92% +/- 3.3% and 50 +/- 3.5% for patients with localized LCL and disseminated LCL, respectively. After adjustment for lactate dehydrogenase (LDH), age at diagnosis, and BM involvement, short and intensive therapy as delivered on the most recent study, CCG-5911, was associated with an improved outcome (P< 0.05) compared to the four previous studies. Elevated LDH (> or = 500 IU/L) at diagnosis and young age (<5 years) were both significant independent predictors of poorer long-term EFS (P< 0.05). Long-term survival after relapse or other treatment failure was only 31% +/- 4.7%. In summary, more recent shorter and intense therapy appears to be associated with superior event-free survival for children and adolescents with disseminated LCL. Large numbers of patients treated with shorter and intense therapy are required to confirm these preliminary observations.
American Journal of Hematology 01/2003; 72(1):53-63. · 4.67 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In 1975, members of The Childrens Cancer Group (CCG) initiated a trial for patients with infratentorial medulloblastomas and ependymomas. Patients, all of whom received post-operative cranio-spinal irradiation (CSI), were randomized to receive or not receive adjuvant chemotherapy (CT) with lomustine (CCNU), vincristine, and prednisone for 1 year. Thirty-six of the 42 patients with ependymoma entered on study were suitable for analysis; 22 received combined modality therapy and 14 irradiation (RT) alone. The failure-free survival (FFS) for the entire sample at 10 years is 36% and overall survival (OS) 39%, with no difference in outcomes between the two regimens. Survival was better for females (73%) than males (21%) and for those older than 10 years (51% vs. 31%). There were two toxic deaths in the group receiving CT. We conclude from this study with long-term follow-up that the CT used was not effective in improving the outcome in children with ependymoma. © 1996 Wiley-Liss, Inc.
Medical and Pediatric Oncology 06/1996; 27(1):8 - 14.
-
IRB Ethics and Human Research 25(4):7-11.
-
IRB Ethics and Human Research 31(3):17-9.
